Central serous chorioretinopathy in patients receiving exogenous testosterone therapy

Retina. 2014 Oct;34(10):2128-32. doi: 10.1097/IAE.0000000000000198.

Abstract

Purpose: To report an association between central serous chorioretinopathy (CSCR) and exogenous testosterone therapy.

Methods: This is a retrospective case series from two institutions. Patients who presented with fluorescein angiography and optical coherence tomography findings consistent with CSCR were included. All patients were concurrently being treated with exogenous testosterone therapy and lacked other known risk factors for CSCR.

Results: Nine patients presented with CSCR after beginning exogenous testosterone therapy. Two patients stopped therapy with resolution of symptoms and subretinal fluid.

Conclusion: Exogenous testosterone may be an independent risk factor for the development of CSCR.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Androgens / adverse effects*
  • Central Serous Chorioretinopathy / chemically induced*
  • Central Serous Chorioretinopathy / diagnosis
  • Central Serous Chorioretinopathy / physiopathology
  • Coloring Agents
  • Fluorescein Angiography
  • Humans
  • Indocyanine Green
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Testosterone / adverse effects*
  • Tomography, Optical Coherence
  • Vision Disorders / chemically induced*
  • Vision Disorders / diagnosis
  • Vision Disorders / physiopathology
  • Visual Acuity / physiology

Substances

  • Androgens
  • Coloring Agents
  • Testosterone
  • Indocyanine Green